AA
RVNC

ALPS Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

ALPS Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-65,366
Closed -$1.62M – 956
2018
Q3 		$1.62M Buy
65,366
+11,952
+22% +$325K 0.01% 278
2018
Q2 		$1.47M Buy
53,414
+5,433
+11% +$163K 0.01% 264
2018
Q1 		$1.48M Buy
47,981
+13,702
+40% +$441K 0.01% 244
2017
Q4 		$1.23M Buy
34,279
+3,928
+13% +$113K 0.01% 227
2017
Q3 		$836K Buy
30,351
+3,027
+11% +$73.4K 0.01% 270
2017
Q2 		$721K Buy
27,324
+2,793
+11% +$62.3K 0.01% 284
2017
Q1 		$510K Sell
24,531
-2,873
-10% -$59K ﹤0.01% 393
2016
Q4 		$567K Sell
27,404
-8,909
-25% -$149K ﹤0.01% 305
2016
Q3 		$589K Sell
36,313
-3,677
-9% -$53.4K ﹤0.01% 253
2016
Q2 		$544K Buy
39,990
+8,431
+27% +$149K ﹤0.01% 240
2016
Q1 		$551K Sell
31,559
-5,409
-15% -$110K 0.01% 207
2015
Q4 		$1.26M Sell
36,968
-513
-1% -$17.8K 0.01% 206
2015
Q3 		$11.2K Buy
37,481
+13,743
+58% +$417K 0.01% 211
2015
Q2 		$759K Buy
23,738
+11,954
+101% +$307K 0.01% 226
2015
Q1 		$244K Buy
+11,784
New +$204K ﹤0.01% 634

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return

ALPS Advisors's RVNC Position: Q4 2018 in Review

ALPS Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2018, closing a stake of 65,366 shares — an estimated $1.62M sold.

ALPS Advisors first reported a position in RVNC in Q1 2015 and held it in 15 quarters. The position peaked at $1.62M in Q3 2018. 101 funds tracked by Wall St. Rank hold RVNC as of Q4 2018.

  • ALPS Advisors reported no remaining Revance Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • ALPS Advisors sold 65,366 Revance Therapeutics, Inc. shares in Q4 2018, an estimated $1.62M.
  • ALPS Advisors first reported a position in Revance Therapeutics, Inc. in Q1 2015 and held it in 15 quarters.
  • ALPS Advisors's Revance Therapeutics, Inc. position peaked at $1.62M in Q3 2018.
  • 101 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2018.

Based on ALPS Advisors's 13F filing for Q4 2018, filed 4 Feb 2019.